Individual biomarkers like G0S2 [34] and BUB1, PINK1 [36,37] might overcome the problem of heterogeneity with CIMP, but those biomarkers merely identify ACC with a poor prognosis. This evidence concerns the gene G0S2 and adrenal cortex carcinoma.